SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read MoreSCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read MoreAfamelanotide for Acute Stroke Patients
EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...
Read MoreMedia Release – CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients...
Read MoreUpdate: SCENESSE® in DNA Repair
CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...
Read MoreMedia Release - First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...
Read MoreFirst patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...
Read MoreMedia Release (ASX) - CLINUVEL progresses innovative DNA Repair Program
Drug tested to protect skin and regenerate DNA, firstly in XP patients...
Read MoreMedia Release – New drug to repair damaged skin and reduce skin cancer risk
Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...
Read MoreSCENESSE® in DNA Repair
CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...
Read MoreMedia Release - Second Afamelanotide Formulation
PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...
Read MorePRÉNUMBRA® – New Liquid Afamelanotide Presentation
EXECUTIVE SUMMARY • PRÉNUMBRA® non-solid dosage form of afamelanotide • Active life-cycle...
Read More